Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2022-01-25 Management Reports
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Management Reports Classification · 95% confidence The document is a 'half-year operational update' from TheraVet. While it contains some financial data (cash position), it is primarily a narrative summary of operational milestones, clinical study results, and commercial launches for the second half of 2021. It does not constitute a full interim financial report (which would require formal financial statements) nor is it a simple announcement of a report. It fits the definition of a Management Report (MDA) as it provides management's detailed explanation of business trends, operational progress, and outlook for the period. H2 2021
2022-01-25 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is titled "TheraVet publie son point d'activité du 2nd semestre 2021" (TheraVet publishes its activity update for the 2nd half of 2021) and explicitly presents key highlights and operational updates for the period ending December 31, 2021. It includes commentary from the CEO, details on clinical results, commercial launches, governance changes, and a cash position update as of the period end. This structure strongly indicates a periodic financial/operational report covering a period shorter than a full year (H2 2021). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), a simple Earnings Release (ER) which usually only contains headline figures, nor is it just an announcement of a report (RPA). H2 2021
2022-01-25 French
TheraVet strengthens its sales organisation in France by signing an important distribution agreement for BIOCERA-VET®
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new commercial distribution agreement between TheraVet and Centravet. It details the strategic partnership, the products involved, and the market impact. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2022-01-18 English
TheraVet renforce son dispositif commercial en France avec la signature d’un important accord de distribution pour le BIOCERA-VET®
Regulatory Filings Classification · 95% confidence The document is a press release issued by TheraVet announcing a new commercial distribution agreement with Centravet for its BIOCERA-VET product line in France. It details the strategic importance of this partnership for market penetration. As it is a general corporate announcement regarding business operations and does not fit into specific categories like financial reports, M&A, or director dealings, it falls under the general regulatory/corporate announcement category.
2022-01-18 French
TheraVet versterkt zijn commerciële slagkracht in Frankrijk na het afsluiten van een belangrijk distributieakkoord voor BIOCERA-VET®
Regulatory Filings Classification · 100% confidence The document is a press release dated January 18, 2022, announcing a significant non-exclusive distribution agreement signed by TheraVet with Centravet for its BIOCERA-VET® products in France. This type of announcement, detailing a strategic business development (a commercial partnership/deal), does not fit the specific definitions for financial reports (10-K, IR, ER), governance documents (CGR, DEF 14A), or shareholder actions (DIV, DVA). It is a general corporate announcement regarding business operations and strategy. Since it is not a report itself, and it is a specific business development announcement, it is best classified as a Regulatory Filing (RNS) as a general announcement, or potentially a general Investor Relations communication. Given the options, RNS serves as the best general regulatory/corporate announcement fallback when a more specific category like M&A (TAR) or Capital Change (CAP) does not apply. However, the document also contains a forward-looking statement about the next press release ('Volgende persbericht: halfjaarlijkse update - H2 2021 25 januari 2022'), which suggests it is an official, timely communication. Since it is a press release announcing a major commercial agreement, and there is no specific 'Commercial Agreement' code, RNS (Regulatory Filings / General Announcement) is the most appropriate fit among the provided codes for a non-standard, material business update.
2022-01-18 Dutch
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated January 18, 2022, announcing a significant commercial distribution agreement for TheraVet's BIOCERA-VET® product in France with Centravet. This type of announcement, detailing strategic business developments, partnerships, or operational milestones outside of mandatory financial reporting (like 10-K, 10-Q, or specific regulatory filings), typically falls under general corporate news or regulatory announcements. Since it is not a formal financial report (ER, IR, 10-K), a management discussion (MDA), a capital event (CAP, SHA), or a director dealing (DIRS), the most appropriate classification is the general regulatory/corporate announcement category, RNS, as it is a formal communication to the market about a material event. The document length is short (4279 chars) and it is a direct announcement, not an announcement *of* a report, so RPA is not the best fit.
2022-01-18 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.